

ESP Advanced Training Centre in the area of Molecular Pathology Heidelberg, Germany

Specialist fields and techniques (open also to technicians/medical scientists)

Molecular pathology

Centre specification

Name of the centre and address

Institute of Pathology
University Hospital Heidelberg
Im Neuenheimer Feld 224
69120 Heidelberg

Chair of the centre

Prof. Dr. P. Schirmacher

Head of the training programme

Prof. Dr. A. Stenzinger

Details about specific training areas (particular method, field of subspeciality)

Molecular Pathology

Conditions

The center will offer one trainee position in Molecular Pathology at a time. The duration should be not more than 3 months, shorter periods are possible for applicants with advanced knowledge. We accept applicants all year round except for middle December till middle of January and during August/beginning of September. We will not charge the training and support will be given in finding an accommodation for a reasonable local price. If required we will support the applicant to obtain the necessary visa and other documents and send a letter of invitation as well as we will agree on duration and time of the stay beforehand. After completion of the training period the trainee will receive a detailed certificate describing the work.

Contact address for requests

Dr. Mandy Skunde
Institute of Pathology
Im Neuenheimer Feld 224, room 1.007
69120 Heidelberg
Tel: +49/ 6221 56 39186
Email: mandy.skunde@med.uni-heidelberg.de

Attachments:

1. Training measures
2. Publications of the last 5 years

Attachment 1:

Molecular Pathology training measures:

- Participation in processing/evaluation of daily routine cases (~7000 cases p.a.)

- Hands- on training in molecular pathology center (wet lab and dry lab; tissue and liquid fluids)
- Participation in molecular pathology research project
- Participation in internal training measures (5 h weekly)
 - Bioinformatics meeting (1h weekly)
 - Challenging Molecular Cases meeting (1h weekly)
 - Research Meeting (1h weekly)
 - Journal Club (1 h weekly)
- Participation in regular interdisciplinary meetings (2 h weekly)
 - Molecular tumor board with NCT (2 h weekly)

Trainers (Board certified Pathologists with high expertise in Molecular Pathology and experienced Molecular Biologists with routine molecular pathology expertise):

Dr. A. Stenzinger

Dr. A.-L. Volckmar

Dr. M. Kirchner

Dr. O. Neumann

Dr. A. Fink.

Dr. D. Kazdal

Dr. J. Budczies

Dr. M. Menzel

Attachment 2:

Publications of the last 5 years:

Nakken S, Edsjö A, Lehtiö J, Nygaard V, Roepman P, Rosenquist R, Russnes HG, Stenzinger A, Tamborero D, Zhao S; PCM4EU consortium; Hovig E. **Towards an ecosystem of clinical decision support tools for precision cancer medicine.** NPJ Precis Oncol. 2026 Jun 17. doi: 10.1038/s41698-026-01551-6. Online ahead of print. PMID: 42310422

Altbürger C, Menzel M, Beck S, Lorenz K, Brygider ML, Ploeger C, Kahles A, Ball M, Kirchner M, Schnecko F, Jung A, Klauschen F, Grob T, Horst D, Hirsch D, Evert M, Schirmacher P, Budczies J, Kazdal D, Stenzinger A. **Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing.** Br J Cancer. 2026 Jun;134(12):1810-1819. doi: 10.1038/s41416-026-03422-0. Epub 2026 Apr 7. PMID: 4194683

Ball M, Beck S, Wlochowicz D, Fuchs T, Lorenz K, Zgorzelski C, Pallares Robles A, Allgäuer M, Volckmar AL, Goldschmid H, Ourailidis I, Brandt R, Christopoulos P, Thomas M, Seker-Cin H, Fink A, Schnecko F, Neumann O, Menzel M, Kirchner M, Fioretos T, Schirmacher P, Peters S, Budczies J, Stenzinger A, Kazdal D. **Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples.** Br J Cancer. 2026 Apr;134(7):1101-1110. doi: 10.1038/s41416-025-03307-8. Epub 2026 Jan 14. PMID: 41530577

Allgäuer M, Kluck K, Christopoulos P, Ball M, Volckmar AL, Radonic T, Bubendorf L, Hofman P, Heußel CP, Winter H, Herth F, Thomas M, Ylstra B, Peters S, Schirmacher P, Kazdal D, Budczies J, Stenzinger A, Kirchner M. **Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to**

Delineate Tumor Origins. J Thorac Oncol. 2026 Feb;21(2):267-282. doi: 10.1016/j.jtho.2025.10.010. Epub 2025 Oct 22. PMID: 41135642

Kahles A, Volckmar AL, Goldschmid H, Salto-Tellez M, Vogeser M, Stone J, Brüggemann M, Budczies J, Kazdal D, Salgado R, Schirmacher P, Peters S, Lennerz JK, Stenzinger A. **Regulation of laboratory-developed tests and in-house in vitro diagnostic medical devices in the United States and the European Union-a comparative overview.** ESMO Open. 2025 Dec;10(12):105909. doi: 10.1016/j.esmoop.2025.105909. Epub 2025 Nov 26. PMID: 41308513

Menzel M, Martis-Thiele M, Goldschmid H, Ott A, Romanovsky E, Siemanowski-Hrach J, Seillier L, Brühle NO, Maurer A, Lehmann KV, Begemann M, Elbracht M, Meyer R, Dintner S, Claus R, Meier-Kolthoff JP, Blanc E, Möbs M, Joosten M, Benary M, Basitta P, Hölscher F, Tischler V, Groß T, Kutz O, Prause R, William D, Horny K, Goering W, Sivalingam S, Borkhardt A, Blank C, Junk SV, Yasin L, Moskalev EA, Carta MG, Ferrazzi F, Tögel L, Wolter S, Adam E, Matysiak U, Rosenthal T, Dönitz J, Lehmann U, Schmidt G, Bartels S, Hofmann W, Hirsch S, Dikow N, Göbel K, Banan R, Hamelmann S, Fink A, Ball M, Neumann O, Rehker J, Kloth M, Murtagh J, Hartmann N, Jurmeister P, Mock A, Kumbrink J, Jung A, Mayr EM, Jacob A, Trautmann M, Kirmse S, Falkenberg K, Ruckert C, Hirsch D, Immel A, Dietmaier W, Haack T, Marienfeld R, Fürstberger A, Niewöhner J, Gerstenmaier U, Eberhardt T, Greif PA, Appenzeller S, Maurus K, Doll J, Jelting Y, Jonigk D, Märkl B, Beule D, Horst D, Wulf AL, Aust D, Werner M, Reuter-Jessen K, Ströbel P, Auber B, Sahm F, Merkelbach-Bruse S, Siebolts U, Roth W, Lassmann S, Klauschen F, Gaisa NT, Weichert W, Evert M, Armeanu-Ebinger S, Ossowski S, Schroeder C, Schaaf CP, Malek N, Schirmacher, Kazdal D, Budczies J, Stenzinger A **Benchmarking whole exome sequencing in the German network for personalized medicine.** Eur J Cancer. 2024 Nov;211:114306. doi: 10.1016/j.ejca.2024.114306. Epub 2024 Sep 8. PMID: 39293347

Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bièche I, Bonastre J, Castro E, Dienstmann R, Krämer A, Czarnecka AM, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, André F. **Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.** Ann Oncol. 2024 Jul;35(7):588-606. doi: 10.1016/j.annonc.2024.04.005. Epub 2024 May 27. PMID: 38834388

Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, Boerries M, Wolter S, Ball M, Neumann O, Armeanu-Ebinger S, Schroeder C, Matysiak U, Goldschmid H, Schipperges V, Fürstberger A, Allgäuer M, Eberhardt T, Niewöhner J, Blaumeiser A, Ploeger C, Haack TB, Tay TKY, Kelemen O, Pauli T, Kirchner M, Kluck K, Ott A, Renner M, Admard J, Gschwind A, Lassmann S, Kestler H, Fend F, Illert AL, Werner M, Möller P, Seufferlein TTW, Malek N, Schirmacher P, Fröhling S, Kazdal D, Budczies J, Stenzinger A. **Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.** NPJ Precis Oncol. 2023 Oct 20;7(1):106. doi: 10.1038/s41698-023-00457-x. PMID: 37864096

Stenzinger A, Moltzen EK, Winkler E, Molnar-Gabor F, Malek N, Costescu A, Jensen BN, Nowak F, Pinto C, Ottersen OP, Schirmacher P, Nordborg J, Seufferlein T, Fröhling S, Edsjö A, Garcia-Foncillas J, Normanno N, Lundgren B, Friedman M, Bolanos N, Tatton-Brown K, Hill S, Rosenquist R. **Implementation of precision medicine in healthcare-A European perspective.** J Intern Med. 2023 Oct;294(4):437-454. doi: 10.1111/joim.13698. Epub 2023 Jul 26. PMID: 37455247

Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, Thimme R, Fioretos T, Bitzer M, Cavalier L, Schirmacher P, Malek N, Rosenquist R; GMS working group

and ZPM working group. **Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany.** Semin Cancer Biol. 2022 Sep;84:242-254. doi: 10.1016/j.semcancer.2021.05.026. Epub 2021 May 24. PMID: 34033893

Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, Ducreux M; ESMO Guidelines Committee. **Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.** Ann Oncol. 2023 Feb;34(2):127-140. doi: 10.1016/j.annonc.2022.10.506. Epub 2022 Nov 10. PMID: 36372281

Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campreggher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. **Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC).** Genet Med. 2022 May;24(5):986-998. doi: 10.1016/j.gim.2022.01.001. Epub 2022 Jan 29. PMID: 35101336

Stenzinger A, Alber M, Allgäuer M, Jurmeister P, Bockmayr M, Budczies J, Lennerz J, Eschrich J, Kazdal D, Schirmacher P, Wagner AH, Tacke F, Capper D, Müller KR, Klauschen F. **Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling.** Semin Cancer Biol. 2022 Sep;84:129-143. doi: 10.1016/j.semcancer.2021.02.011. Epub 2021 Feb 22. PMID: 33631297